

Fourth Edition

Current
C A N C E R
Therapeutics

John M. Kirkwood, MD

Professor and Chief, Division of Medical Oncology, University of Pittsburgh School of Medicine;
Chief, Melanoma Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania

Michael T. Lotze, MD

Vice President and Director, Departments of Inflammation, Tissue Repair, and Oncology,
SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania

Joyce M. Yasko, PhD

Professor, School of Nursing, University of Pittsburgh;
Associate Director, Clinical and Network Programs, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania

With 69 contributors



Developed by Current Medicine, Inc., Philadelphia

VCTC Library

CURRENT MEDICINE, INC.

400 Market Street
Suite 700
Philadelphia, PA 19106

DEVELOPMENTAL EDITOR: *Elise M. Paxson*

DESIGNER: *Christine Keller-Quirk*

ASSISTANT PRODUCTION MANAGER: *Simon Dickey*

EDITORIAL ASSISTANT: *Janet Gilmore*

ILLUSTRATOR: *Wiesia Langenfeld*

The Editors thank Rowena Schwartz, Pharm. D., for pharmaceutical review of the manuscripts.

Current Medicine Inc. grants authorization to photocopy items for educational, classroom, or internal use, and to republish in print, Internet, CD-ROM, slide, or other media, provided that the appropriate fee is paid directly to Copyright Clearance Center Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (Tel: (978) 750-8400; Fax: (978) 750-4470; E-mail: info@copyright.com; Website: <http://www.copyright.com>). For permission for other uses, please contact the Permissions Department, Current Medicine Inc., 400 Market Street, Suite 700, Philadelphia, PA 19106-2514, USA.

Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publishers nor the authors can be held responsible for errors or for any consequences arising from the use of information contained herein. Products mentioned in this publication should be used in accordance with the prescribing information prepared by the manufacturers. No claims or endorsements are made for any drug or compound at present under clinical investigation.

For more information please call 1-800-427-1796 or e-mail us at inquiry@phl.cursci.com
www.current-science-group.com

ISBN: 1-57340-176-5

ISSN: 1074-2816

Printed in the United States of America by Port City Press.

5 4 3 2 1

Copyright© 2001, 1998, 1996, 1994 by Current Medicine, Inc. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means electronic, mechanical, photocopying, recording, or otherwise, without prior written permission of the publisher.

CONTENTS

PART 1: AGENTS

1. ALKYLATING AND PLATINATING AGENTS.....	1
<i>Stanton L. Gerson</i>	
2. ANTIMETABOLIC AGENTS.....	37
<i>Judy Chiao, Julie Beitz, Robert J. DeLap</i>	
3. BIOLOGIC AGENTS.....	55
<i>Ulrich Kielholz, Michael T. Lotze</i>	
4. HORMONAL AGENTS.....	76
<i>Douglas Yee, David T. Kiang</i>	
5. TUBULIN-TARGETING DRUGS.....	95
<i>Johann Sebastian de Bono, Anthony W. Tolcher, Eric K. Rowinsky</i>	

PART 2: SPECIFIC NEOPLASMS AND THERAPEUTIC PROTOCOLS

6. BREAST CANCER.....	109
<i>Minetta C. Liu, Marc E. Lippman</i>	
7. UPPER GASTROINTESTINAL CANCER.....	130
<i>Kevin F. Staveley-O'Carroll, Herbert J. Zeh, Margaret A. Tempero</i>	
8. LOWER GASTROINTESTINAL CANCER.....	150
<i>Jean L. Grem</i>	
9. HEAD AND NECK CANCER.....	163
<i>Roger Stupp, Everett E. Vokes</i>	
10. LUNG CANCER.....	177
<i>Carlos William de Araujo, Paul A. Bunn, Jr</i>	
11. MELANOMA AND OTHER TUMORS OF THE SKIN.....	205
<i>Michael T. Lotze, John M. Kirkwood</i>	
12. SARCOMAS.....	217
<i>Ronald H. Blum, Herbert J. Zeh, David L. Bartlett</i>	
13. GENITOURINARY CANCER.....	230
<i>Marc S. Ernstoff, Christopher Tretter, John A. Heaney</i>	
14. GYNECOLOGIC MALIGNANCIES.....	250
<i>Scott Wadler</i>	
15. MALIGNANT GLIOMA.....	266
<i>Michael Prados</i>	
16. ENDOCRINE CANCER.....	275
<i>Jennifer Lowney, Gerard M. Doherty</i>	
17. LEUKEMIA.....	287
<i>Edward D. Ball, Edwin Alyea, Jerome Ritz</i>	

18. HODGKIN'S DISEASE.....	301
<i>Alan R. Yuen, Sandra J. Horning</i>	
19. NON-HODGKIN'S LYMPHOMA.....	310
<i>Dorothy Pan, Carol S. Portlock</i>	
20. MYELOMA.....	323
<i>James R. Berenson</i>	
21. MALIGNANT EFFUSIONS IN THE CHEST.....	334
<i>John C. Ruckdeschel, David Jablons</i>	
22. CARCINOMA OF UNKNOWN PRIMARY.....	340
<i>Melanie B. Thomas, James L. Abbruzzese</i>	
23. AIDS-RELATED MALIGNANCIES.....	349
<i>Ashfin Dowlati, Scot C. Remick</i>	

PART 3: SUPPORTIVE CARE

24. PALLIATIVE CARE.....	367
<i>Robert M. Arnold, Linda King</i>	
25. MYELOSUPPRESSION.....	374
<i>Michael S. Gordon</i>	
26. GASTROINTESTINAL TOXICITIES.....	382
<i>John Hobneker, Tom Lampkin, Paul Wissel</i>	
27. RENAL AND METABOLIC COMPLICATIONS.....	392
<i>Janet A. Amico, Jean L. Holley, Sai Subhodhini Reddy</i>	
28. PULMONARY AND CARDIOVASCULAR COMPLICATIONS OF CANCER THERAPY.....	406
<i>Matthew Volm, Howard Hochster</i>	
29. NEUROTOXICITIES.....	414
<i>Tjeerd J. Postma</i>	
30. EVALUATION OF QUALITY OF LIFE IN CANCER CLINICAL TRIALS.....	421
<i>Bernard F. Cole, Richard D. Gelber, Shari Gelber</i>	
31. SYSTEMIC MANIFESTATIONS OF CANCER AND MANAGEMENT OF SYSTEMIC PARANEOPLASTIC SYNDROMES.....	427
<i>Jayesh Desai, Michelle Gold, Sonia Fullerton, Jonathan Cebon</i>	
32. MALNUTRITION.....	442
<i>Yuman Fong, Stephen F. Lowry</i>	

PART 4: CLINICAL TRIAL DATA COLLECTION

33. CLINICAL TRIALS: MONITORING AND REPORTING OF TOXICITIES, AND EVALUATING TUMOR RESPONSE.....	455
<i>Linda Barry Robertson</i>	
34. SYNOPTIC PATHOLOGY REPORTS.....	459
<i>Michael J. Becich</i>	
INDEX.....	481

CHAPTER 25: MYELOSUPPRESSION

Michael S. Gordon

Patients receiving chemotherapy or radiation therapy experience certain side effects. Some (eg, acute nausea and vomiting) occur acutely and are managed with medications or intravenous fluids designed to counteract these effects. Other side-effects (eg, alopecia), although uncomfortable and perhaps damaging in terms of patient self-image, are not dangerous and do resolve at the conclusion of therapy. Among all side effects seen, those associated with the effects of anticancer therapy on the bone marrow (BM) represent a potentially dangerous and even life-threatening circumstance [1]. Because most anticancer treatments affect rapidly dividing cells preferentially, BM is an ideal target for these effects. This is the primary reason that myelosuppression is among the complications most frequently seen.

Temporary damage to BM can result in decreases in all three major strains of peripheral blood, although effects on leukocytes and especially the myeloid series tend to dominate, given that they have the shortest survival of all BM-derived cells (Table 25-1). This results in a drop in the infection-fighting neutrophil series, with an associated increased risk of infection. Although these patients are at increased risk for both bacterial and fungal forms of infection, the former tends to be more commonly seen. Generally, only patients with long-term severely low (absolute neutrophil count < 250 cells/ μ L) for lengthy periods experience mycotic infections. Bodey *et al.* [2] reviewed the experience at the National Institutes of Health leukemia service, which defined that both the depth and duration of neutropenia play roles in the risk of developing systemic infectious complications. Because in most cases, neutropenia is of a short duration, the average risk of infection with standard chemotherapy is relatively low. Among the remaining lineages, anemia is most often cumulative in nature. A current controversy disputes which level of anemia represents a sufficiently significant drop to warrant intervention with medical therapy even though transfusion therapy continues to be a mainstay of management of this side effect. This complication most often lowers patients' quality of life by fatiguing them. Finally, a small percentage of patients develops clinically significant thrombocytopenia from cancer therapy. The risk of clinically severe bleeding in patients with thrombocytopenia is low and occurs primarily when the platelet count falls to dangerously low levels. Overall, development of myelosuppression as a complication of cancer therapy can be related to a range of variables (Table 25-2); the development of other complications such as disseminated intravascular coagulopathy or other underlying illness can complicate this issue.

PATHOPHYSIOLOGY

Production of blood cells by BM is an orderly process controlled by both positive and negative regulators termed hematopoietic growth factors (HGFs) and cytokines (Table 25-3) [2]. These include both early-acting stem cell factors (primarily interleukins 1, 3, 6, as well as

stem cell factors) and the lineage-specific colony-stimulating factors (eg, granulocyte colony-stimulating factors [G-CSF], granulocyte-macrophage colony-stimulating factors [GM-CSF], and erythropoietin). These biologic agents control the proliferation, differentiation, and maturation of multipotential precursor cells that can be directed to various lineages based on the relative expression of specific factors in a BM microenvironment. Hematologic lineages are regulated by a series of feedback loops such as that of the renal tubules that control erythropoietin expression in response to hematocrit.

Blood cell production begins with the multipotential stem cell, which has the ability to self replicate and thereby ensure that adequate precursor cells are always available. The exhaustion of this stem cell supply, although theoretical, could lead to severe BM aplasia and hypoproduction of all blood cells. Although BM aplasia as a result of cancer therapy is rare, it generally only happens with the most intensive chemotherapy regimens.

In general, the environment in which the stem cells exist needs to be conducive to their growth and development. Severe fibrosis from diseases, such as the myeloproliferative disorders or chronic changes as a result of radiation therapy, tends to make BM space inhospitable to blood cell production. This therefore can contribute significantly to the development of myelosuppression.

Kinetically, the myelosuppressive effects of cancer therapy tend to be related to what stage of development is damaged by the agent in question. Neutrophils, which usually survive 7 hours in circulation, are most sensitive to treatment effects. Similarly, platelets that last 7 to 10 days are more commonly affected than erythrocytes, which last 120 days in circulation. The progression of hematopoietic development is similar for all lineages taking approximately 7 days to progress from stem cell to committed progenitor and another 7 to 10 days to progress from committed progenitor to mature cell, ready for release into the circulation. It is this latter 7- to 10-day period that can be compressed by the available CSFs to accelerate blood cell production rapidly.

CAUSES

The principal forms of cancer therapy that cause myelosuppression are chemotherapy and radiation therapy. In the case of radiation, the damaging effect is not limited to the hematopoietic compartment, but to the marrow microenvironment itself. Not uncommonly, it can take up to several years for recovery of a previously irradiated area. In

Table 25-1. Categories of Cytopenias

Lineage	Approximate Survival (in Circulation)	Deficiency
Myeloid	7 h	Neutropenia
Erythroid	120 d	Anemia
Megakaryocyte	7-10 d	Thrombocytopenia

Table 25-2. Factors Associated With Myelosuppression

Therapy
Choice of chemotherapy agents and dose-intensity
Radiation therapy including total dose and volume radiated
Bone marrow reserve
Patient's age and nutritional status
Prior therapy
Bone marrow involvement with malignancy or other process
Bone marrow involvement with cancer or other process
Comorbid conditions such as autoimmune processes
Drug-related effects (nonchemotherapy)
Infection-related complications (ie, disseminated intravascular coagulation)

MYELOSUPPRESSION

contrast to these two therapies, biologic therapy (eg, immunotherapy) may cause myelosuppression by inducing a peripheral consumptive state related to hypersplenism or some similar mechanism. This former effect most commonly resolves quickly following discontinuation of these agents. In some cases of antibody-directed irradiation (using a monoclonal antibody to target radiation particles), the impact can be more significant.

Chemotherapy

Chemotherapy affects hematologic cells in much the same way it does cancer cells. Chemotherapy drugs can be classified into categories based on mechanism of action. Alkylating agents typically bind to nucleotide bases of DNA and thereby inhibit protein synthesis and replication. This effect is similar to that of the antitumor antibiotics such as doxorubicin or daunorubicin that intercalate into DNA strands, thus preventing DNA synthesis. Vinca alkaloids (vincristine or vinblastine) and the taxanes (paclitaxel and docetaxel) inhibit microtubular synthesis that inhibits spindle formation preventing cells from actively undergoing mitosis. Finally, antimetabolites frequently substitute themselves for purine or pyrimidine nucleotides, thereby blocking DNA or RNA synthesis. These latter agents may also block specific enzymes required for nucleotide synthesis. BM cells take up these chemotherapy drugs in much the same way as cancer cells. Hence, BM, because of its rapidly proliferating state, often tends to be more sensitive to the effects of chemotherapy because unlike cancer cells, these progenitors often lack mechanisms of resistance to the chemotherapy. An outline of cancer chemotherapeutic agents and their relative effects on different lines is shown in Table 25-4. Several agents such as vincristine, low-dose methotrexate, L-asparaginase, and oral cyclophosphamide generally do not cause significant myelosuppression. Conversely, agents such as the nitrosureas and mitomycin-C frequently induce delayed and prolonged myelosuppression because of their relative effects on the stem cell population.

Immunotherapy

Biologic agents can be divided into two specific groups with regard to their effects on the hematologic system. The first group, which includes the interferons (alfa, beta, and gamma), can exert a direct suppressive effect on BM and although not specifically myelotoxic,

certainly is not myelosuppressive. This impact on blood counts is typically relatively rapidly reversible after the drug has been discontinued. In contrast, lymphopenia and neutropenia associated with interleukin-2 (IL-2) appear to be predominantly related to peripheral consumption by immunostimulated cells or by vascular margination of pools of cells. Both these side effects are rapidly reversible, appear to be dose related, and generally are not associated with infectious complications. In addition to the IL-2-mediated neutropenia, this agent has the ability to induce neutrophil dysfunction, which lasts longer than quantitative neutropenia and may be associated with increased infectious risk.

Radiation Therapy

Radiation therapy induces cell death by causing lethal double-stranded DNA breaks. These DNA breaks result in cell death and apoptosis when the cell enters the cell cycle. For this reason, it is cells in G₀ that tend to be more sensitive to DNA damage than those in G₁ or S-phase, which tend to be more resistant due to their ability to correct damage enzymatically. Hence, myelosuppression associated with radiation therapy is often related to the volume of BM irradiated, the total radiation dose, and the patient's overall BM reserve (which may be compromised by either prior therapy or BM involvement with cancer).

DIAGNOSIS

The first evidence of myelosuppression is often a defined drop in the number of peripherally circulating blood cells. Because of the kinetics and life span of blood cells as previously noted, leukopenia and neutropenia are typically the first deficiencies noted. This drop, which may be mild, is frequently found 7 to 10 days following the completion of therapy, although more intensive treatments may accelerate the process. In the case of moderately to severely intensive regimens, thrombocytopenia may be noted at or around the same time. Anemia, as a side-effect of therapy, is more commonly cumulative and develops over time or a series of cycles.

In typical situations, response to the development of cytopenias is an increase in BM production of blood cells. This generally corrects mild leukopenia or thrombocytopenia in a short time (7 to 14 days). In some cases, in which more severe or prolonged myelosuppression occurs, further investigation may be necessary.

Table 25-3. Hematopoietic Growth Factors and Cytokines

	Name	Lineage	Approval Status
Colony-stimulating factors	C-CSF	m	Approved
	GM-CSF	m, mo	Approved
	EPO	e	Approved
	TPO	p	Investigational
	M-CSF	mo	No longer under study
Interleukins	Interleukin-11	p	Approved
	Interleukin-3	m, e, p	No longer under study
	Interleukin-6	p	No longer under study
	Interleukin-1	m, e, p	No longer under study

e—erythroid; G-CSF—granulocyte colony-stimulating factor; GM-CSF—granulocyte-macrophage colony-stimulating factor; EPO—erythropoietin; m—myeloid; mo—monocytic; M-CSF—macrophage colony-stimulating factor; p—platelet; TPO—thrombopoietin.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.